Adams Delaney S, Conaway Brandon D, Farrar Julie E, Byerly Saskya, Filiberto Dina M, Dickerson Roland N
Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Department of Pharmacy, Regional One Health, Memphis, TN 38103, USA.
Nutrients. 2025 Sep 5;17(17):2880. doi: 10.3390/nu17172880.
The aim of this study was to retrospectively evaluate the results of administering subcutaneous neutral protamine Hagedorn (NPH) insulin every 8 h (NPH-8) versus every 12 h (NPH-12) in critically ill, hyperglycemic trauma patients who required continuous enteral nutrition (EN).
Both groups of patients were given concurrent sliding scale regular human insulin (SSI) with NPH therapy. The evaluation of glycemic control continued for 7 days.
A total of 15 patients were given NPH every 8 h (NPH-8), and 19 were given NPH every 12 h (NPH-12). Carbohydrate intake was similar between groups (115 ± 35 vs. 108 ± 37 g/d; = 0.584). There was no significant difference in average blood glucose (BG) concentration (168 ± 18 vs. 166 ± 17 mg/dL; = 0.803) or time within a BG target range of 70 to 149 mg/dL (7.5 ± 4.7 vs. 8.1 ± 5.0 h/d; = 0.678) or 70 to 179 mg/dL (14.5 ± 5.0 vs. 16 ± 5.6 h/d; = 0.419) or the incidence of Level 1 hypoglycemia (2 patients in each group; = 1.00) or Level 2 hypoglycemia (1 patient vs. 0 patients, = 0.441) between the NPH-8 and NPH-12 groups, respectively. However, the NPH-8 group required twice as much total (NPH + SSI) insulin (115 ± 52 vs. 58 ± 33 units/d; = 0.004).
These preliminary data suggest no significant difference between the administration of NPH-8 and NPH-12 based on glycemic control metrics in critically ill hyperglycemic trauma patients given EN. However, these results may be confounded by a selection bias as to who received NPH-8 vs. NPH-12. Further research is required.
本研究旨在回顾性评估在需要持续肠内营养(EN)的重症高血糖创伤患者中,每8小时皮下注射中性鱼精蛋白锌胰岛素(NPH)(NPH - 8)与每12小时注射(NPH - 12)的效果。
两组患者在接受NPH治疗的同时均给予常规胰岛素滑动剂量治疗(SSI)。血糖控制评估持续7天。
共有15例患者每8小时接受一次NPH注射(NPH - 8组),19例患者每12小时接受一次NPH注射(NPH - 12组)。两组间碳水化合物摄入量相似(115±35 vs. 108±37克/天;P = 0.584)。平均血糖(BG)浓度(168±18 vs. 166±17毫克/分升;P = 0.803)、血糖在70至149毫克/分升目标范围内的时间(7.5±4.7 vs. 8.1±5.0小时/天;P = 0.678)、血糖在70至179毫克/分升目标范围内的时间(14.5±5.0 vs. 16±5.6小时/天;P = 0.419)、1级低血糖发生率(每组2例患者;P = 1.00)或2级低血糖发生率(1例患者vs. 0例患者,P = 0.441)在NPH - 8组和NPH - 12组之间均无显著差异。然而,NPH - 8组所需的总胰岛素量(NPH + SSI)是NPH - 12组的两倍(115±52 vs. 58±33单位/天;P = 0.004)。
这些初步数据表明,在接受EN的重症高血糖创伤患者中,基于血糖控制指标,NPH - 8和NPH - 12给药之间无显著差异。然而,这些结果可能因NPH - 8与NPH - 12的选择偏倚而混淆。需要进一步研究。